Cytokinetics bags FDA breakthrough therapy status for aficamten in oHCM
Cytokinetics has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). According to the US-based biopharma company, Aficamten is a cardiac myosin inhibitor, which is being developed for the potential treatment of hypertrophic cardiomyopathy. In patients with hypertrophic cardiomyopathy, the heart […]